CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 451 enrolled
Drug / intervention
liraglutide +1 moredrug
Likely dose
liraglutide 1.8 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01617434
NCT01617434Phase 3Completed
CompareCT.gov

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Novo Nordisk A/S·interventional·Posted Jun 12, 2012·Updated Mar 8, 2017

In Brief

A Phase 3 clinical trial evaluating liraglutide and placebo for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 451 participants across 86 sites in 9 countries.

Detailed Summary

This trial is conducted in Asia, Europe and North and South America. The aim of the trial is to investigate the effect of liraglutide versus placebo when added to basal insulin analogues with or without metformin in subjects with type 2 diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesArgentina, Canada, Finland, Germany, India, Mexico, Netherlands, Serbia, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 12, 2012
Enrollment StartSep 1, 2012
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 14.1 years ago

Interventions

liraglutidedrug

Maximum 1.8 mg administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.

placebodrug

Placebo administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.